| ERBB2 drives YAP activation and EMT-like processes during cardiac regeneration A Aharonov, A Shakked, KB Umansky, A Savidor, A Genzelinakh, D Kain, ... Nature cell biology 22 (11), 1346-1356, 2020 | 162 | 2020 |
| Mechanical interplay between invadopodia and the nucleus in cultured cancer cells OY Revach, A Weiner, K Rechav, I Sabanay, A Livne, B Geiger Scientific reports 5 (1), 9466, 2015 | 87 | 2015 |
| The interplay between the proteolytic, invasive, and adhesive domains of invadopodia and their roles in cancer invasion OY Revach, B Geiger Cell adhesion & migration 8 (3), 215-225, 2014 | 74 | 2014 |
| Biomechanical regulation of focal adhesion and invadopodia formation OY Revach, I Grosheva, B Geiger Journal of cell science 133 (20), jcs244848, 2020 | 73 | 2020 |
| Targeting TBK1 to overcome resistance to cancer immunotherapy Y Sun, O Revach, S Anderson, EA Kessler, CH Wolfe, A Jenney, CE Mills, ... Nature 615 (7950), 158-167, 2023 | 64 | 2023 |
| 20S proteasomes secreted by the malaria parasite promote its growth E Dekel, D Yaffe, I Rosenhek-Goldian, G Ben-Nissan, Y Ofir-Birin, ... Nature communications 12 (1), 1172, 2021 | 64 | 2021 |
| Longitudinal characterization of circulating neutrophils uncovers phenotypes associated with severity in hospitalized COVID-19 patients TJ LaSalle, ALK Gonye, SS Freeman, P Kaplonek, I Gushterova, KR Kays, ... Cell Reports Medicine 3 (10), 2022 | 45 | 2022 |
| Cross-talk between receptor tyrosine kinases AXL and ERBB3 regulates invadopodia formation in melanoma cells OY Revach, O Sandler, Y Samuels, B Geiger Cancer Research 79 (10), 2634-2648, 2019 | 42 | 2019 |
| Targeting TANK-binding kinase 1 (TBK1) in cancer OY Revach, S Liu, RW Jenkins Expert opinion on therapeutic targets 24 (11), 1065-1078, 2020 | 41 | 2020 |
| Immunomodulatory Properties of Leishmania Extracellular Vesicles During Host-Parasite Interaction: Differential Activation of TLRs and NF-κB Translocation by … PM Nogueira, A de Menezes-Neto, VM Borges, A Descoteaux, ... Frontiers in Cellular and Infection Microbiology 10, 380, 2020 | 36 | 2020 |
| The involvement of mutant Rac1 in the formation of invadopodia in cultured melanoma cells OY Revach, SE Winograd-Katz, Y Samuels, B Geiger Experimental cell research 343 (1), 82-88, 2016 | 34 | 2016 |
| Malaria parasites both repress host CXCL10 and use it as a cue for growth acceleration Y Ofir-Birin, H Ben Ami Pilo, A Cruz Camacho, A Rudik, A Rivkin, ... Nature communications 12 (1), 4851, 2021 | 28 | 2021 |
| Sialylated N‐glycans mediate monocyte uptake of extracellular vesicles secreted from Plasmodium falciparum‐infected red blood cells H Ben Ami Pilo, S Khan Khilji, J Lühle, K Biskup, B Levy Gal, ... Journal of Extracellular Biology 1 (2), e33, 2022 | 9 | 2022 |
| Proliferation and EMT trigger heart repair A González-Iglesias, MA Nieto Nature Cell Biology 22 (11), 1291-1292, 2020 | 4 | 2020 |
| Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy OY Revach, AM Cicerchia, O Shorer, B Petrova, S Anderson, J Park, ... bioRxiv, 2024 | | 2024 |
| In vivo gain-of-function screen identifies CREB5, a novel ECM modulator that promotes immunotherapy resistance via the Collagen-Lair1 axis P Tiwari, K Colvin, S Kim, A Kammula, S Anderson, OY Revach, M Vyas, ... CANCER IMMUNOLOGY RESEARCH 11 (12), 2023 | | 2023 |
| Abstract B021: In vivo gain-of-function screen identifies CREB5, a novel ECM modulator that promotes immunotherapy resistance via the Collagen-Lair1 axis P Tiwari, K Colvin, S Kim, A Kammula, S Anderson, OY Revach, M Vyas, ... Cancer Immunology Research 11 (12_Supplement), B021-B021, 2023 | | 2023 |
| 628 Circulatory plasma proteomic biomarkers combined with high-throughput proteomic screen of patient-derived organotypic tumor spheroids predict responses to immunotherapy in … M Rucevic, A Mehta, RW Jenkins, A Kar, A Cicerchia, OY Revach, Y Sun, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 561 Targeting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy OY Revach, A Cicerchia, M Sade-Feldman, S Anderson, B Petrova, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Targeting CD38 on exhausted T cells overcomes resistance to cancer immunotherapy OY Revach, AM Cicerchia, M Sade-Feldman, S Anderson, RT Manguso, ... Cancer Research 83 (7_Supplement), 3250-3250, 2023 | | 2023 |
